BH Cell Co., Ltd. announced that it has received KRW 7.5 billion in funding from Cellumed Co., Ltd. and other investors
August 30, 2021
Share
BH Cell Co., Ltd. announced that it will issue 1,500,000 common shares at a par value of KRW 5,000 per share for gross proceeds of KRW 7,500,000,000 on August 31, 2021. The transaction included participation from new individual investors, Hyun, Yoo Myung for KRW 200,000, Young-Duk Lee for KRW 200,000, Hyun, Woo-sung for KRW 200,000, Jungwook Moon for KRW 100,000, Yoo, In-soo for KRW 200,000, Kim, Kwang-seok for KRW 180,000, Kim, Boo-seok for KRW 40,000, Shin, Sung-hyun for KRW 20,000, Seo-Jun Lee for KRW 100,000, Lee, Seon-ja for KRW 60,000, Hyo-soon Moon for KRW 40,000, Choong-Sung Lee for KRW 10,000, returning investor Cellumed Co., Ltd. for KRW 150,000 for 10% stake in the company. The transaction has been approved by the board of directors. The capital increase method is through 3rd party allocation. The payment date of the transaction is August 31, 2021.
CELLUMED CO., LTD., formerly Korea Bone Bank CO., LTD, is a Korea-based company engaged in the manufacture and sale of medical equipment and biosimilars. The Companyâs products consist of allografts for tissue repair; bone sponges, bone powders and demineralized bone matrixes (DBMs) for bone regeneration; biosimilars, such as bone morphogenetic protein 2 (BMP2) reagents and others, as well as medical devices, such as spinal fixation systems, joint replacements and navigation systems. The Company sells its products within domestic market and to overseas markets.
CELLUMED CO.,LTD. 
